Usefulness of PET with 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer

Journal of Nuclear Medicine

Volumn 41, Issue 2, 2000, Pages 283-290

  Yasukawa, Tomohisa ^a   Yoshikawa, Kyosan ^b   Aoyagi, Hisayuki ^b   Yamamoto, Naoyoshi ^b   Tamura, Katsumi ^b   Suzuki, Kazutoshi ^b   Tsujii, Hirohiko ^b   Murata, Hajime ^b   Sasaki, Yasuhito ^b   Fujisawa, Takehiko ^b  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

11C methionine; Lung cancer; Lymph node metastasis; PET

Indexed keywords

METHIONINE C 11; NONIONIC CONTRAST MEDIUM; CARBON; CARBON 11 METHIONINE; CARBON-11 METHIONINE; DIAGNOSTIC AGENT; METHIONINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG HILUS; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LUNG TUMOR; LYMPH NODE; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; ROC CURVE; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

CARBON RADIOISOTOPES; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; METHIONINE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0033621985     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Staples CA, Muller NL, Miller RR, Evans KG, Nelems B. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology. 1988;167:367-372.
2. Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology. 1991;178:705-713.
3. McLoud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology. 1992;182:319-323.
4. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cadiovasc Surg. 1996;111:642-648.
5. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med. 1994;21:741-747.
6. 18FDG in patients with bronchogenic carcinoma. Chest. 1995;108: 1617-1621.
7. 18F]FDG positron emission tomography (PET). Thorax. 1997;52:438-441.
8. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J. 1996;9:2560-2564.
9. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology. 1997;202:441-446.
10. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 1998;16:2142-2149.
11. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med. 1990;31: 1927-1933.
12. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 1992;33:325-329.
13. Brooks RA, Di Chiro G, Miletich RS. PET and NMR studies of brain tumors at the National Institute of Health. Tumor Diagn Ther. 1988;9:172.
14. Bustany P, Chatel M, Derlon JM, et al. Brain tumor protein synthesis and histological grades: a study by positron emission tomography (PET) with C-11-L-methionine. J Neurooncol. 1986;3:397-404.
15. Ichiya Y, Kuwabara Y, Otsuka M, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med. 1991;32:1655-1660.
16. Miyazawa H, Arai T, Iio M, Hara T. PET imaging of non-small cell lung carcinoma with carbon-11-methionine: relationship between radioactivity uptake and flow-cytometric parameters. J Nucl Med. 1993;34:1886-1891.
17. Inoue T, Kim EE, Wong FCL, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors. J Nucl Med. 1996;37:1472-1476.
18. Hoffman RM. Altered methionine metabolism, DNA methylation and oncogenic expression in carcinogenesis. Biochem Biophys Acta. 1984;738:49-87.
19. Mecham JO, Rowitch D, Wallace CD, Stern PH, Hoffman RM. The metabolic defect of methionine dependence occurs frequently in human tumor cell lines. Biochem Biophys Res Commun. 1983;117:429-434.
20. 11C]methionine quantitation in cancer PET studies. J Comput Assist Tomogr. 1992;16:468-474.
21. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
22. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409-1415.